查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
藥物警戒市場——按類型（軟件、服務(按流程、按活動(自發報告、增強的不良事件報告、隊列事件監測）、臨床試驗階段、服務提供商、最終用途、預測，2023-2032 年
市場調查報告書
商品編碼
1280657

藥物警戒市場——按類型（軟件、服務(按流程、按活動(自發報告、增強的不良事件報告、隊列事件監測）、臨床試驗階段、服務提供商、最終用途、預測，2023-2032 年

Pharmacovigilance Market-By Type (Software, Service {By Process, By Activity [Spontaneous Reporting, Intensified Adverse Drug Reaction Reporting, Cohort Event Monitoring]}), By Clinical Trial Phase, Service Provider, By End-use, & Forecast, 2023-2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 246 Pages | 商品交期: 2-3個工作天內

價格

全球藥物警戒市場將從 2023 年增長到 2032 年，這得益於對藥物警戒不斷增長的需求以及對數據驅動洞察力的需求，以確保患者安全，預計將出現顯著增長。

此外，隨著嚴格的藥品審批監管要求，對新藥和創新藥的需求不斷增加，預計將推動未來十年的市場增長。

藥物不良反應 (ADR) 和藥物毒性發生率的上升推動了對藥物警戒的需求。 由於這些療法的種類和可用性不斷增加，必須密切監測它們的安全性和有效性。 藥物警戒對於確保藥物的益處超過可能的風險的重要性推動了產品的採用。 此外，全球人口的持續激增和慢性病患病率的上升也推動了對藥物安全的需求。 根據疾病預防控制中心的數據，每年約有 877,500 名美國人死於心髒病。

疾病負擔的增加以及更多專注於有前途的合作夥伴關係和合併以引領行業的主要市場參與者將有利於市場增長。 例如，2023 年 4 月，德國製藥公司 PharmaLex 宣布與澳大利亞和新西蘭藥物警戒提供商 Cpharm 進行戰略合併。 通過這種合作關係，兩家公司的目標是在澳大利亞市場提供端到端的解決方案，並擴大他們的醫療服務和客戶群。

藥物警戒市場在類型、臨床試驗階段、服務提供商、最終用途和地區方面存在分歧。

根據臨床試驗階段，到 2032 年底，2 期部分預計將達到 4.1 億美元以上。 將進行第二階段試驗，以評估候選藥物在大量患有相關疾病或病症的患者中的安全性和有效性。 全球範圍內越來越多的臨床試驗增加了對強大的藥物警戒系統的需求，以在這些試驗期間監測和確保患者安全。

就最終用途而言，醫療器械公司細分市場的藥物警戒市場價值到 2022 年將超過 25 億美元。 藥物警戒服務提供商為公司提供醫療器械安全概況，從處理和報告單個不良事件到將產品撤出市場作為現場安全糾正措施的一部分。 監管機構越來越關注醫療器械的上市後監督和安全監測，這推動了產品的採用。

預計從 2023 年到 2032 年，亞太地區的藥物警戒市場將呈現出驚人的複合年增長率。 這是由於大量的外包機構。 生產力、成本效率和資源共享的提高預計將在未來幾年增加區域對藥物警戒的需求。 此外，人口基數的擴大以及藥物攝入量和醫療保健需求的增加也補充了該地區的市場增長。

內容

第一章研究方法與範圍

第 2 章執行摘要

第 3 章藥物警戒行業洞察

  • 行業細分
  • 2018-2032 年行業格局
  • 影響行業的因素
    • 司機
      • 對新藥的需求不斷增長
      • 製藥公司增加研發投資
      • 藥物不良反應 (ADR) 和藥物毒性的發生率增加
      • 對個性化醫療越來越感興趣
      • 藥物警戒服務外包的趨勢增加
    • 行業潛在的風險和挑戰
      • 與數據安全相關的高風險
      • 缺乏熟練的醫療保健專業人員
  • 增長潛力分析
    • 按類型
    • 按臨床試驗階段
    • 按服務提供商
    • 按最終用途
  • COVID-19 影響分析
  • 監管狀況
    • 美國
    • 歐洲
  • 技術/情況
    • 藥物警戒中的人工智能 (AI)
    • 藥物警戒中的自然語言處理 (NLP)
  • 波特分析
  • PESTEL 分析

第 4 章競爭格局，2022 年

  • 簡介
  • 公司矩陣分析，2022 年
  • 各公司的定位矩陣
  • 主要市場參與者的競爭分析
  • 戰略視角矩陣
  • 公司股票分析，2022 年
  • 戰略儀表板 (2022)

第 5 章藥物警戒市場：按類型

  • 主要類型趨勢
  • 軟件
  • 服務
    • 按流程
      • 核心服務
      • 諮詢服務
    • 按活動
      • 自願報告
      • 增強的副作用 (ADR) 報告
      • 隊列事件監控
      • 電子病歷挖掘
      • 其他

第 6 章藥物警戒市場：按臨床試驗階段

  • 主要臨床試驗階段的趨勢
  • 臨床前研究
  • 第一階段
  • 第 2 階段
  • 第 3 階段
  • 第 4 階段

第 7 章藥物警戒市場：按服務提供商分類

  • 主要服務提供商趨勢
  • 內部
  • 外包合同

第 8 章藥物警戒市場：按最終用途分類

  • 主要最終用途的趨勢
  • 製藥和生物技術公司
  • 醫療設備製造商
  • 醫院
  • 其他

第 9 章藥物警戒市場：按地區

  • 主要區域趨勢
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 其他拉丁美洲地區
  • 中東和非洲
    • 南非
    • 沙特阿拉伯
    • 阿聯酋
    • 卡塔爾
    • 以色列
    • 其他中東和非洲地區

第十章公司簡介

  • Accenture
  • Cognizant
  • Labcorp Drug Development
  • IBM Corporation
  • ArisGlobal
  • ICON plc
  • United BioSource LLC
  • Pharmaceutical Development Group, Inc.
  • Wipro Limited
  • Allucent
Product Code: 853

Global Pharmacovigilance Market is expected to showcase remarkable growth over 2023-2032, driven by the increasing demand for drug safety monitoring and the need for data-driven insights to ensure patient safety. In addition, increasing demand for new and innovative drugs, in line with stringent regulatory requirements for drug approval, will fuel market growth over the next ten years.

The rising incidence rate of adverse drug reactions (ADR) and drug toxicity is encouraging the demand for pharmacovigilance. The safety and effectiveness of these treatments need to be closely monitored, given their increasing diversity and availability. The importance of pharmacovigilance in ensuring that the advantages of medicines outweigh any possible hazards is pushing product adoption. Moreover, the consistent surge in the global population and increased prevalence of chronic diseases have also propelled the need for drug safety. According to CDC, around 877.500 Americans die of heart strokes each year.

The growing disease burden and the increasing focus of key market players on promising partnerships and mergers to stay ahead in the industry will favor market growth. For instance, in April 2023, PharmaLex, a German pharmaceutical firm, announced a strategic merger with Cpharm, a pharmacovigilance provider in Australia and New Zealand. With this alliance, the companies aim to offer end-to-end solutions in the Australian market and expand their medical services & customer base.

The pharmacovigilance market is bifurcated in terms of type, clinical trial phase, service provider, end-use, and region.

Based on the clinical trial phase, the phase 2 segment is expected to reach over $410 million by the end of 2032. This second stage of trials is conducted to evaluate the safety and efficacy of a drug candidate in a larger group of patients with the target disease or condition. The rising number of clinical trials worldwide is fueling the need for robust pharmacovigilance systems to monitor and ensure patient safety during these trials.

With respect to end-use, the pharmacovigilance market value from the medical device companies segment was over $2.5 billion in 2022. Pharmacovigilance service providers supply medical device safety profiles to companies, ranging from the processing and reporting of single adverse incidents through the withdrawal of products from the market as part of a Field Safety Corrective Action. The greater emphasis of regulatory bodies on post-market surveillance and safety monitoring of medical devices is bolstering product uptake.

Asia Pacific pharmacovigilance market is expected to exhibit an appreciable CAGR between 2023 and 2032, attributed to the availability of numerous outsourcing organizations. The increasing productivity, cost efficiency, and resource sharing are expected to drive regional demand for pharmacovigilance in the upcoming years. Additionally, the expanding population base with increased drug intake and healthcare demand are also complementing the regional market growth.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Industry coverage
  • 1.2 Market scope and definitions
  • 1.3 Base estimates and working
  • 1.4 Forecast parameters
  • 1.5 COVID-19 impact analysis at global level
  • 1.6 Data validation
  • 1.7 Data sources
    • 1.7.1 Primary
    • 1.7.2 Secondary
      • 1.7.2.1 Paid sources
      • 1.7.2.2 Unpaid sources

Chapter 2 Executive Summary

  • 2.1 Pharmacovigilance industry 360 degree synopsis, 2018 - 2032
    • 2.1.1 Business trends
    • 2.1.2 Type trends
    • 2.1.3 Clinical trial phase trends
    • 2.1.4 Service provider trends
    • 2.1.5 End-user trends
    • 2.1.6 Regional trends

Chapter 3 Pharmacovigilance Industry Insights

  • 3.1 Industry segmentation
  • 3.2 Industry landscape, 2018 - 2032
  • 3.3 Industry impact forces
    • 3.3.1 Growth drivers
      • 3.3.1.1 Increasing need of new drugs
      • 3.3.1.2 Rising investment on R&D by pharmaceutical companies
      • 3.3.1.3 Rise in incidences of adverse drug reactions (ADR) and drug toxicity
      • 3.3.1.4 Increasing focus on personalized medicine
      • 3.3.1.5 Increasing trend of outsourcing pharmacovigilance services
    • 3.3.2 Industry pitfalls & challenges
      • 3.3.2.1 High risk associated with data security
      • 3.3.2.2 Lack of skilled healthcare professionals
  • 3.4 Growth potential analysis
    • 3.4.1 By type
    • 3.4.2 By clinical trial phase
    • 3.4.3 By service provider
    • 3.4.4 By end-use
  • 3.5 COVID-19 impact analysis
  • 3.6 Regulatory landscape
    • 3.6.1 U.S.
    • 3.6.2 Europe
  • 3.7 Technology landscape
    • 3.7.1 Artificial intelligence (AI) in pharmacovigilance
    • 3.7.2 Natural language processing (NLP) in pharmacovigilance
  • 3.8 Porter's analysis
  • 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

  • 4.1 Introduction
  • 4.2 Company matrix analysis, 2022
  • 4.3 Company positioning matrix
  • 4.4 Competitive analysis of major market players
  • 4.5 Strategic outlook matrix
  • 4.6 Company market share analysis, 2022
  • 4.7 Strategy dashboard, 2022

Chapter 5 Pharmacovigilance Market, By Type

  • 5.1 Key type trends
  • 5.2 Software
    • 5.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
  • 5.3 Service
    • 5.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
    • 5.3.2 By Process
      • 5.3.2.1 Core services
        • 5.3.2.1.1 Market estimates and forecast, 2018 - 2032 (USD Million)
      • 5.3.2.2 Consulting services
        • 5.3.2.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
    • 5.3.3 By Activity
      • 5.3.3.1 Spontaneous Reporting
        • 5.3.3.1.1 Market estimates and forecast, 2018 - 2032 (USD Million)
      • 5.3.3.2 Intensified Adverse Drug Reaction (ADR) Reporting
        • 5.3.3.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
      • 5.3.3.3 Cohort Event Monitoring
        • 5.3.3.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
      • 5.3.3.4 EHR Mining
        • 5.3.3.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
      • 5.3.3.5 Others
        • 5.3.3.5.1 Market estimates and forecast, 2018 - 2032 (USD Million)

Chapter 6 Pharmacovigilance Market, By Clinical Trial Phase

  • 6.1 Key clinical trial phase trends
  • 6.2 Pre-clinical
    • 6.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
  • 6.3 Phase 1
    • 6.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
  • 6.4 Phase 2
    • 6.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
  • 6.5 Phase 3
    • 6.5.1 Market estimates and forecast, 2018 - 2032 (USD Million)
  • 6.6 Phase 4
    • 6.6.1 Market estimates and forecast, 2018 - 2032 (USD Million)

Chapter 7 Pharmacovigilance Market, By Service Provider

  • 7.1 Key service provider trends
  • 7.2 In-house
    • 7.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
  • 7.3 Contract outsourcing
    • 7.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)

Chapter 8 Pharmacovigilance Market, By End-use

  • 8.1 Key end-use trends
  • 8.2 Pharmaceutical & biotechnological companies
    • 8.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
  • 8.3 Medical device companies
    • 8.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
  • 8.4 Hospitals
    • 8.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
  • 8.5 Others
    • 8.5.1 Market estimates and forecast, 2018 - 2032 (USD Million)

Chapter 9 Pharmacovigilance Market, By Region

  • 9.1 Key regional trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Italy
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 India
    • 9.4.3 Japan
    • 9.4.4 Australia
    • 9.4.5 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
    • 9.5.4 Rest of Latin America
  • 9.6 Middle East & Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE
    • 9.6.4 Qatar
    • 9.6.5 Israel
    • 9.6.6 Rest of Middle East & Africa

Chapter 10 Company Profiles

  • 10.1 Accenture
  • 10.2 Cognizant
  • 10.3 Labcorp Drug Development
  • 10.4 IBM Corporation
  • 10.5 ArisGlobal
  • 10.6 ICON plc
  • 10.7 United BioSource LLC
  • 10.8 Pharmaceutical Development Group, Inc.
  • 10.9 Wipro Limited
  • 10.10 Allucent

Data Tables

  • TABLE 1. Market revenue, by type, 2022
  • TABLE 2. Market revenue, by clinical trial phase, 2022
  • TABLE 3. Market revenue, by service provider, 2022
  • TABLE 4. Market revenue, by end-use, 2022
  • TABLE 5. Market share, by region, 2022
  • TABLE 6. Global pharmacovigilance market, 2018-2022 (USD Million)
  • TABLE 7. Global pharmacovigilance market, 2023 - 2032 (USD Million)
  • TABLE 8. Global pharmacovigilance market, by type, 2018-2022 (USD Million)
  • TABLE 9. Global pharmacovigilance market, by type, 2023 - 2032 (USD Million)
  • TABLE 10. Global pharmacovigilance market, by clinical trial phase, 2018-2022 (USD Million)
  • TABLE 11. Global pharmacovigilance market, by clinical trial phase, 2023 - 2032 (USD Million)
  • TABLE 12. Global pharmacovigilance market, by service provider, 2018-2022 (USD Million)
  • TABLE 13. Global pharmacovigilance market, by service provider, 2023 - 2032 (USD Million)
  • TABLE 14. Global pharmacovigilance market, by end-use, 2018-2022 (USD Million)
  • TABLE 15. Global pharmacovigilance market, by end-use, 2023 - 2032 (USD Million)
  • TABLE 16. Global pharmacovigilance market, region, 2018-2022 (USD Million)
  • TABLE 17. Global pharmacovigilance market, region, 2023 - 2032 (USD Million)
  • TABLE 18. Industry impact forces
  • TABLE 19. Software market estimates and forecast, 2018-2022 (USD Million)
  • TABLE 20. Software market estimates and forecast, 2023 - 2032 (USD Million)
  • TABLE 21. Service market estimates and forecast, 2018-2022 (USD Million)
  • TABLE 22. Service market estimates and forecast, 2023 - 2032 (USD Million)
  • TABLE 23. Core services market estimates and forecast, 2018-2022 (USD Million)
  • TABLE 24. Core services market estimates and forecast, 2023 - 2032 (USD Million)
  • TABLE 25. Consulting services market estimates and forecast, 2018-2022 (USD Million)
  • TABLE 26. Consulting services market estimates and forecast, 2023 - 2032 (USD Million)
  • TABLE 27. Spontaneous reporting market estimates and forecast, 2018-2022 (USD Million)
  • TABLE 28. Spontaneous reporting market estimates and forecast, 2023 - 2032 (USD Million)
  • TABLE 29. Intensified Adverse Drug Reaction (ADR) reporting market estimates and forecast, 2018-2022 (USD Million)
  • TABLE 30. Intensified Adverse Drug Reaction (ADR) reporting market estimates and forecast, 2023 - 2032 (USD Million)
  • TABLE 31. Cohort event monitoring market estimates and forecast, 2018-2022 (USD Million)
  • TABLE 32. Cohort event monitoring market estimates and forecast, 2023 - 2032 (USD Million)
  • TABLE 33. EHR mining market estimates and forecast, 2018-2022 (USD Million)
  • TABLE 34. EHR mining market estimates and forecast, 2023 - 2032 (USD Million)
  • TABLE 35. Other activities market estimates and forecast, 2018-2022 (USD Million)
  • TABLE 36. Other activities market estimates and forecast, 2023 - 2032 (USD Million)
  • TABLE 37. Pre-clinical animals market estimates and forecast, 2018-2022 (USD Million)
  • TABLE 38. Pre-clinical animals market estimates and forecast, 2023 - 2032 (USD Million)
  • TABLE 39. Phase 1 market estimates and forecast, 2018-2022 (USD Million)
  • TABLE 40. Phase 1 market estimates and forecast, 2023 - 2032 (USD Million)
  • TABLE 41. Phase 2 market estimates and forecast, 2018-2022 (USD Million)
  • TABLE 42. Phase 2 market estimates and forecast, 2023 - 2032 (USD Million)
  • TABLE 43. Phase 3 market estimates and forecast, 2018-2022 (USD Million)
  • TABLE 44. Phase 3 market estimates and forecast, 2023 - 2032 (USD Million)
  • TABLE 45. Phase 4 and goats market estimates and forecast, 2018-2022 (USD Million)
  • TABLE 46. Phase 4 and goats market estimates and forecast, 2023 - 2032 (USD Million)
  • TABLE 47. In-house market estimates and forecast, 2018-2022 (USD Million)
  • TABLE 48. In-house market estimates and forecast, 2023 - 2032 (USD Million)
  • TABLE 49. Contract outsourcing market estimates and forecast, 2018-2022 (USD Million)
  • TABLE 50. Contract outsourcing market estimates and forecast, 2023 - 2032 (USD Million)
  • TABLE 51. Pharmaceutical & biotechnological companies market estimates and forecast, 2018-2022 (USD Million)
  • TABLE 52. Pharmaceutical & biotechnological companies market estimates and forecast, 2023 - 2032 (USD Million)
  • TABLE 53. Medical device companies market estimates and forecast, 2018-2022 (USD Million)
  • TABLE 54. Medical device companies market estimates and forecast, 2023 - 2032 (USD Million)
  • TABLE 55. Hospitals market estimates and forecast, 2018-2022 (USD Million)
  • TABLE 56. Hospitals market estimates and forecast, 2023 - 2032 (USD Million)
  • TABLE 57. Others market estimates and forecast, 2018-2022 (USD Million)
  • TABLE 58. Others market estimates and forecast, 2023 - 2032 (USD Million)
  • TABLE 59. North America pharmacovigilance market, by country, 2018-2022 (USD Million)
  • TABLE 60. North America pharmacovigilance market, by country, 2023 - 2032 (USD Million)
  • TABLE 61. North America pharmacovigilance market, by type, 2018-2022 (USD Million)
  • TABLE 62. North America pharmacovigilance market, by type, 2023 - 2032 (USD Million)
  • TABLE 63. North America pharmacovigilance market, by process, 2018-2022 (USD Million)
  • TABLE 64. North America pharmacovigilance market, by process, 2023-2032 (USD Million)
  • TABLE 65. North America pharmacovigilance market, by activity, 2018-2022 (USD Million)
  • TABLE 66. North America pharmacovigilance market, by activity, 2023-2032 (USD Million)
  • TABLE 67. North America pharmacovigilance market, by clinical trial phase, 2018-2022 (USD Million)
  • TABLE 68. North America pharmacovigilance market, by clinical trial phase, 2023 - 2032 (USD Million)
  • TABLE 69. North America pharmacovigilance market, by service provider, 2018-2022 (USD Million)
  • TABLE 70. North America pharmacovigilance market, by service provider, 2023-2032 (USD Million)
  • TABLE 71. North America pharmacovigilance market, by end-use, 2018-2022 (USD Million)
  • TABLE 72. North America pharmacovigilance market, by end-use, 2023 - 2032 (USD Million)
  • TABLE 73. U.S. pharmacovigilance market, by type, 2018-2022 (USD Million)
  • TABLE 74. U.S. pharmacovigilance market, by type, 2023 - 2032 (USD Million)
  • TABLE 75. U.S. pharmacovigilance market, by process, 2018-2022 (USD Million)
  • TABLE 76. U.S. pharmacovigilance market, by process, 2023-2032 (USD Million)
  • TABLE 77. U.S. pharmacovigilance market, by activity, 2018-2022 (USD Million)
  • TABLE 78. U.S. pharmacovigilance market, by activity, 2023-2032 (USD Million)
  • TABLE 79. U.S. pharmacovigilance market, by clinical trial phase, 2018-2022 (USD Million)
  • TABLE 80. U.S. pharmacovigilance market, by clinical trial phase, 2023 - 2032 (USD Million)
  • TABLE 81. U.S. pharmacovigilance market, by service provider, 2018-2022 (USD Million)
  • TABLE 82. U.S. pharmacovigilance market, by service provider, 2023-2032 (USD Million)
  • TABLE 83. U.S. pharmacovigilance market, by end-use, 2018-2022 (USD Million)
  • TABLE 84. U.S. pharmacovigilance market, by end-use, 2023 - 2032 (USD Million)
  • TABLE 85. Canada pharmacovigilance market, by type, 2018-2022 (USD Million)
  • TABLE 86. Canada pharmacovigilance market, by type, 2023 - 2032 (USD Million)
  • TABLE 87. Canada pharmacovigilance market, by process, 2018-2022 (USD Million)
  • TABLE 88. Canada pharmacovigilance market, by process, 2023-2032 (USD Million)
  • TABLE 89. Canada pharmacovigilance market, by activity, 2018-2022 (USD Million)
  • TABLE 90. Canada pharmacovigilance market, by activity, 2023-2032 (USD Million)
  • TABLE 91. Canada pharmacovigilance market, by clinical trial phase, 2018-2022 (USD Million)
  • TABLE 92. Canada pharmacovigilance market, by clinical trial phase, 2023 - 2032 (USD Million)
  • TABLE 93. Canada pharmacovigilance market, by service provider, 2018-2022 (USD Million)
  • TABLE 94. Canada pharmacovigilance market, by service provider, 2023-2032 (USD Million)
  • TABLE 95. Canada pharmacovigilance market, by end-use, 2018-2022 (USD Million)
  • TABLE 96. Canada pharmacovigilance market, by end-use, 2023 - 2032 (USD Million)
  • TABLE 97. Europe pharmacovigilance market, by country, 2018-2022 (USD Million)
  • TABLE 98. Europe pharmacovigilance market, by country, 2023 - 2032 (USD Million)
  • TABLE 99. Europe pharmacovigilance market, by type, 2018-2022 (USD Million)
  • TABLE 100. Europe pharmacovigilance market, by type, 2023 - 2032 (USD Million)
  • TABLE 101. Europe pharmacovigilance market, by process, 2018-2022 (USD Million)
  • TABLE 102. Europe pharmacovigilance market, by process, 2023-2032 (USD Million)
  • TABLE 103. Europe pharmacovigilance market, by activity, 2018-2022 (USD Million)
  • TABLE 104. Europe pharmacovigilance market, by activity, 2023-2032 (USD Million)
  • TABLE 105. Europe pharmacovigilance market, by clinical trial phase, 2018-2022 (USD Million)
  • TABLE 106. Europe pharmacovigilance market, by clinical trial phase, 2023 - 2032 (USD Million)
  • TABLE 107. Europe pharmacovigilance market, by service provider, 2018-2022 (USD Million)
  • TABLE 108. Europe pharmacovigilance market, by service provider, 2023-2032 (USD Million)
  • TABLE 109. Europe pharmacovigilance market, by end-use, 2018-2022 (USD Million)
  • TABLE 110. Europe pharmacovigilance market, by end-use, 2023 - 2032 (USD Million)
  • TABLE 111. Germany pharmacovigilance market, by type, 2018-2022 (USD Million)
  • TABLE 112. Germany pharmacovigilance market, by type, 2023 - 2032 (USD Million)
  • TABLE 113. Germany pharmacovigilance market, by process, 2018-2022 (USD Million)
  • TABLE 114. Germany pharmacovigilance market, by process, 2023-2032 (USD Million)
  • TABLE 115. Germany pharmacovigilance market, by activity, 2018-2022 (USD Million)
  • TABLE 116. Germany pharmacovigilance market, by activity, 2023-2032 (USD Million)
  • TABLE 117. Germany pharmacovigilance market, by clinical trial phase, 2018-2022 (USD Million)
  • TABLE 118. Germany pharmacovigilance market, by clinical trial phase, 2023 - 2032 (USD Million)
  • TABLE 119. Germany pharmacovigilance market, by service provider, 2018-2022 (USD Million)
  • TABLE 120. Germany pharmacovigilance market, by service provider, 2023-2032 (USD Million)
  • TABLE 121. Germany pharmacovigilance market, by end-use, 2018-2022 (USD Million)
  • TABLE 122. Germany pharmacovigilance market, by end-use, 2023 - 2032 (USD Million)
  • TABLE 123. UK pharmacovigilance market, by type, 2018-2022 (USD Million)
  • TABLE 124. UK pharmacovigilance market, by type, 2023 - 2032 (USD Million)
  • TABLE 125. UK pharmacovigilance market, by process, 2018-2022 (USD Million)
  • TABLE 126. UK pharmacovigilance market, by process, 2023-2032 (USD Million)
  • TABLE 127. UK pharmacovigilance market, by activity, 2018-2022 (USD Million)
  • TABLE 128. UK pharmacovigilance market, by activity, 2023-2032 (USD Million)
  • TABLE 129. UK pharmacovigilance market, by clinical trial phase, 2018-2022 (USD Million)
  • TABLE 130. UK pharmacovigilance market, by clinical trial phase, 2023 - 2032 (USD Million)
  • TABLE 131. UK pharmacovigilance market, by service provider, 2018-2022 (USD Million)
  • TABLE 132. UK pharmacovigilance market, by service provider, 2023-2032 (USD Million)
  • TABLE 133. UK pharmacovigilance market, by end-use, 2018-2022 (USD Million)
  • TABLE 134. UK pharmacovigilance market, by end-use, 2023 - 2032 (USD Million)
  • TABLE 135. France pharmacovigilance market, by type, 2018-2022 (USD Million)
  • TABLE 136. France pharmacovigilance market, by type, 2023 - 2032 (USD Million)
  • TABLE 137. France pharmacovigilance market, by process, 2018-2022 (USD Million)
  • TABLE 138. France pharmacovigilance market, by process, 2023-2032 (USD Million)
  • TABLE 139. France pharmacovigilance market, by activity, 2018-2022 (USD Million)
  • TABLE 140. France pharmacovigilance market, by activity, 2023-2032 (USD Million)
  • TABLE 141. France pharmacovigilance market, by clinical trial phase, 2018-2022 (USD Million)
  • TABLE 142. France pharmacovigilance market, by clinical trial phase, 2023 - 2032 (USD Million)
  • TABLE 143. France pharmacovigilance market, by service provider, 2018-2022 (USD Million)
  • TABLE 144. France pharmacovigilance market, by service provider, 2023-2032 (USD Million)
  • TABLE 145. France pharmacovigilance market, by end-use, 2018-2022 (USD Million)
  • TABLE 146. France pharmacovigilance market, by end-use, 2023 - 2032 (USD Million)
  • TABLE 147. Italy pharmacovigilance market, by type, 2018-2022 (USD Million)
  • TABLE 148. Italy pharmacovigilance market, by type, 2023 - 2032 (USD Million)
  • TABLE 149. Italy pharmacovigilance market, by process, 2018-2022 (USD Million)
  • TABLE 150. Italy pharmacovigilance market, by process, 2023-2032 (USD Million)
  • TABLE 151. Italy pharmacovigilance market, by activity, 2018-2022 (USD Million)
  • TABLE 152. Italy pharmacovigilance market, by activity, 2023-2032 (USD Million)
  • TABLE 153. Italy pharmacovigilance market, by clinical trial phase, 2018-2022 (USD Million)
  • TABLE 154. Italy pharmacovigilance market, by clinical trial phase, 2023 - 2032 (USD Million)
  • TABLE 155. Italy pharmacovigilance market, by service provider, 2018-2022 (USD Million)
  • TABLE 156. Italy pharmacovigilance market, by service provider, 2023-2032 (USD Million)
  • TABLE 157. Italy pharmacovigilance market, by end-use, 2018-2022 (USD Million)
  • TABLE 158. Italy pharmacovigilance market, by end-use, 2023 - 2032 (USD Million)
  • TABLE 159. Spain pharmacovigilance market, by type, 2018-2022 (USD Million)
  • TABLE 160. Spain pharmacovigilance market, by type, 2023 - 2032 (USD Million)
  • TABLE 161. Spain pharmacovigilance market, by process, 2018-2022 (USD Million)
  • TABLE 162. Spain pharmacovigilance market, by process, 2023-2032 (USD Million)
  • TABLE 163. Spain pharmacovigilance market, by activity, 2018-2022 (USD Million)
  • TABLE 164. Spain pharmacovigilance market, by activity, 2023-2032 (USD Million)
  • TABLE 165. Spain pharmacovigilance market, by clinical trial phase, 2018-2022 (USD Million)
  • TABLE 166. Spain pharmacovigilance market, by clinical trial phase, 2023 - 2032 (USD Million)
  • TABLE 167. Spain pharmacovigilance market, by service provider, 2018-2022 (USD Million)
  • TABLE 168. Spain pharmacovigilance market, by service provider, 2023-2032 (USD Million)
  • TABLE 169. Spain pharmacovigilance market, by end-use, 2018-2022 (USD Million)
  • TABLE 170. Spain pharmacovigilance market, by end-use, 2023 - 2032 (USD Million)
  • TABLE 171. Rest of Europe pharmacovigilance market, by type, 2018-2022 (USD Million)
  • TABLE 172. Rest of Europe pharmacovigilance market, by type, 2023 - 2032 (USD Million)
  • TABLE 173. Rest of Europe pharmacovigilance market, by process, 2018-2022 (USD Million)
  • TABLE 174. Rest of Europe pharmacovigilance market, by process, 2023-2032 (USD Million)
  • TABLE 175. Rest of Europe pharmacovigilance market, by activity, 2018-2022 (USD Million)
  • TABLE 176. Rest of Europe pharmacovigilance market, by activity, 2023-2032 (USD Million)
  • TABLE 177. Rest of Europe pharmacovigilance market, by clinical trial phase, 2018-2022 (USD Million)
  • TABLE 178. Rest of Europe pharmacovigilance market, by clinical trial phase, 2023 - 2032 (USD Million)
  • TABLE 179. Rest of Europe pharmacovigilance market, by service provider, 2018-2022 (USD Million)
  • TABLE 180. Rest of Europe pharmacovigilance market, by service provider, 2023-2032 (USD Million)
  • TABLE 181. Rest of Europe pharmacovigilance market, by end-use, 2018-2022 (USD Million)
  • TABLE 182. Rest of Europe pharmacovigilance market, by end-use, 2023 - 2032 (USD Million)
  • TABLE 183. Asia Pacific pharmacovigilance market, by country, 2018-2022 (USD Million)
  • TABLE 184. Asia Pacific pharmacovigilance market, by country, 2023 - 2032 (USD Million)
  • TABLE 185. Asia Pacific pharmacovigilance market, by type, 2018-2022 (USD Million)
  • TABLE 186. Asia Pacific pharmacovigilance market, by type, 2023 - 2032 (USD Million)
  • TABLE 187. Asia Pacific pharmacovigilance market, by process, 2018-2022 (USD Million)
  • TABLE 188. Asia Pacific pharmacovigilance market, by process, 2023-2032 (USD Million)
  • TABLE 189. Asia Pacific pharmacovigilance market, by activity, 2018-2022 (USD Million)
  • TABLE 190. Asia Pacific pharmacovigilance market, by activity, 2023-2032 (USD Million)
  • TABLE 191. Asia Pacific pharmacovigilance market, by clinical trial phase, 2018-2022 (USD Million)
  • TABLE 192. Asia Pacific pharmacovigilance market, by clinical trial phase, 2023 - 2032 (USD Million)
  • TABLE 193. Asia Pacific pharmacovigilance market, by service provider, 2018-2022 (USD Million)
  • TABLE 194. Asia Pacific pharmacovigilance market, by service provider, 2023-2032 (USD Million)
  • TABLE 195. Asia Pacific pharmacovigilance market, by end-use, 2018-2022 (USD Million)
  • TABLE 196. Asia Pacific pharmacovigilance market, by end-use, 2023 - 2032 (USD Million)
  • TABLE 197. China pharmacovigilance market, by type, 2018-2022 (USD Million)
  • TABLE 198. China pharmacovigilance market, by type, 2023 - 2032 (USD Million)
  • TABLE 199. China pharmacovigilance market, by process, 2018-2022 (USD Million)
  • TABLE 200. China pharmacovigilance market, by process, 2023-2032 (USD Million)
  • TABLE 201. China pharmacovigilance market, by activity, 2018-2022 (USD Million)
  • TABLE 202. China pharmacovigilance market, by activity, 2023-2032 (USD Million)
  • TABLE 203. China pharmacovigilance market, by clinical trial phase, 2018-2022 (USD Million)
  • TABLE 204. China pharmacovigilance market, by clinical trial phase, 2023 - 2032 (USD Million)
  • TABLE 205. China pharmacovigilance market, by service provider, 2018-2022 (USD Million)
  • TABLE 206. China pharmacovigilance market, by service provider, 2023-2032 (USD Million)
  • TABLE 207. China pharmacovigilance market, by end-use, 2018-2022 (USD Million)
  • TABLE 208. China pharmacovigilance market, by end-use, 2023 - 2032 (USD Million)
  • TABLE 209. India pharmacovigilance market, by type, 2018-2022 (USD Million)
  • TABLE 210. India pharmacovigilance market, by type, 2023 - 2032 (USD Million)
  • TABLE 211. India pharmacovigilance market, by process, 2018-2022 (USD Million)
  • TABLE 212. India pharmacovigilance market, by process, 2023-2032 (USD Million)
  • TABLE 213. India pharmacovigilance market, by activity, 2018-2022 (USD Million)
  • TABLE 214. India pharmacovigilance market, by activity, 2023-2032 (USD Million)
  • TABLE 215. India pharmacovigilance market, by clinical trial phase, 2018-2022 (USD Million)
  • TABLE 216. India pharmacovigilance market, by clinical trial phase, 2023 - 2032 (USD Million)
  • TABLE 217. India pharmacovigilance market, by service provider, 2018-2022 (USD Million)
  • TABLE 218. India pharmacovigilance market, by service provider, 2023-2032 (USD Million)
  • TABLE 219. India pharmacovigilance market, by end-use, 2018-2022 (USD Million)
  • TABLE 220. India pharmacovigilance market, by end-use, 2023 - 2032 (USD Million)
  • TABLE 221. Japan pharmacovigilance market, by type, 2018-2022 (USD Million)
  • TABLE 222. Japan pharmacovigilance market, by type, 2023 - 2032 (USD Million)
  • TABLE 223. Japan pharmacovigilance market, by process, 2018-2022 (USD Million)
  • TABLE 224. Japan pharmacovigilance market, by process, 2023-2032 (USD Million)
  • TABLE 225. Japan pharmacovigilance market, by activity, 2018-2022 (USD Million)
  • TABLE 226. Japan pharmacovigilance market, by activity, 2023-2032 (USD Million)
  • TABLE 227. Japan pharmacovigilance market, by clinical trial phase, 2018-2022 (USD Million)
  • TABLE 228. Japan pharmacovigilance market, by clinical trial phase, 2023 - 2032 (USD Million)
  • TABLE 229. Japan pharmacovigilance market, by service provider, 2018-2022 (USD Million)
  • TABLE 230. Japan pharmacovigilance market, by service provider, 2023-2032 (USD Million)
  • TABLE 231. Japan pharmacovigilance market, by end-use, 2018-2022 (USD Million)
  • TABLE 232. Japan pharmacovigilance market, by end-use, 2023 - 2032 (USD Million)
  • TABLE 233. Australia pharmacovigilance market, by type, 2018-2022 (USD Million)
  • TABLE 234. Australia pharmacovigilance market, by type, 2023 - 2032 (USD Million)
  • TABLE 235. Australia pharmacovigilance market, by process, 2018-2022 (USD Million)
  • TABLE 236. Australia pharmacovigilance market, by process, 2023-2032 (USD Million)
  • TABLE 237. Australia pharmacovigilance market, by activity, 2018-2022 (USD Million)
  • TABLE 238. Australia pharmacovigilance market, by activity, 2023-2032 (USD Million)
  • TABLE 239. Australia pharmacovigilance market, by clinical trial phase, 2018-2022 (USD Million)
  • TABLE 240. Australia pharmacovigilance market, by clinical trial phase, 2023 - 2032 (USD Million)
  • TABLE 241. Australia pharmacovigilance market, by service provider, 2018-2022 (USD Million)
  • TABLE 242. Australia pharmacovigilance market, by service provider, 2023-2032 (USD Million)
  • TABLE 243. Australia pharmacovigilance market, by end-use, 2018-2022 (USD Million)
  • TABLE 244. Australia pharmacovigilance market, by end-use, 2023 - 2032 (USD Million)
  • TABLE 245. Rest of Asia Pacific pharmacovigilance market, by type, 2018-2022 (USD Million)
  • TABLE 246. Rest of Asia Pacific pharmacovigilance market, by type, 2023 - 2032 (USD Million)
  • TABLE 247. Rest of Asia Pacific pharmacovigilance market, by process, 2018-2022 (USD Million)
  • TABLE 248. Rest of Asia Pacific pharmacovigilance market, by process, 2023-2032 (USD Million)
  • TABLE 249. Rest of Asia Pacific pharmacovigilance market, by activity, 2018-2022 (USD Million)
  • TABLE 250. Rest of Asia Pacific pharmacovigilance market, by activity, 2023-2032 (USD Million)
  • TABLE 251. Rest of Asia Pacific pharmacovigilance market, by clinical trial phase, 2018-2022 (USD Million)
  • TABLE 252. Rest of Asia Pacific pharmacovigilance market, by clinical trial phase, 2023 - 2032 (USD Million)
  • TABLE 253. Rest of Asia Pacific pharmacovigilance market, by service provider, 2018-2022 (USD Million)
  • TABLE 254. Rest of Asia Pacific pharmacovigilance market, by service provider, 2023-2032 (USD Million)
  • TABLE 255. Rest of Asia Pacific pharmacovigilance market, by end-use, 2018-2022 (USD Million)
  • TABLE 256. Rest of Asia Pacific pharmacovigilance market, by end-use, 2023 - 2032 (USD Million)
  • TABLE 257. Latin America pharmacovigilance market, by country, 2018-2022 (USD Million)
  • TABLE 258. Latin America pharmacovigilance market, by country, 2023 - 2032 (USD Million)
  • TABLE 259. Latin America pharmacovigilance market, by type, 2018-2022 (USD Million)
  • TABLE 260. Latin America pharmacovigilance market, by type, 2023 - 2032 (USD Million)
  • TABLE 261. Latin America pharmacovigilance market, by process, 2018-2022 (USD Million)
  • TABLE 262. Latin America pharmacovigilance market, by process, 2023-2032 (USD Million)
  • TABLE 263. Latin America pharmacovigilance market, by activity, 2018-2022 (USD Million)
  • TABLE 264. Latin America pharmacovigilance market, by activity, 2023-2032 (USD Million)
  • TABLE 265. Latin America pharmacovigilance market, by clinical trial phase, 2018-2022 (USD Million)
  • TABLE 266. Latin America pharmacovigilance market, by clinical trial phase, 2023 - 2032 (USD Million)
  • TABLE 267. Latin America pharmacovigilance market, by service provider, 2018-2022 (USD Million)
  • TABLE 268. Latin America pharmacovigilance market, by service provider, 2023-2032 (USD Million)
  • TABLE 269. Latin America pharmacovigilance market, by end-use, 2018-2022 (USD Million)
  • TABLE 270. Latin America pharmacovigilance market, by end-use, 2023 - 2032 (USD Million)
  • TABLE 271. Brazil pharmacovigilance market, by type, 2018-2022 (USD Million)
  • TABLE 272. Brazil pharmacovigilance market, by type, 2023 - 2032 (USD Million)
  • TABLE 273. Brazil pharmacovigilance market, by process, 2018-2022 (USD Million)
  • TABLE 274. Brazil pharmacovigilance market, by process, 2023-2032 (USD Million)
  • TABLE 275. Brazil pharmacovigilance market, by activity, 2018-2022 (USD Million)
  • TABLE 276. Brazil pharmacovigilance market, by activity, 2023-2032 (USD Million)
  • TABLE 277. Brazil pharmacovigilance market, by clinical trial phase, 2018-2022 (USD Million)
  • TABLE 278. Brazil pharmacovigilance market, by clinical trial phase, 2023 - 2032 (USD Million)
  • TABLE 279. Brazil pharmacovigilance market, by service provider, 2018-2022 (USD Million)
  • TABLE 280. Brazil pharmacovigilance market, by service provider, 2023-2032 (USD Million)
  • TABLE 281. Brazil pharmacovigilance market, by end-use, 2018-2022 (USD Million)
  • TABLE 282. Brazil pharmacovigilance market, by end-use, 2023 - 2032 (USD Million)
  • TABLE 283. Mexico pharmacovigilance market, by type, 2018-2022 (USD Million)
  • TABLE 284. Mexico pharmacovigilance market, by type, 2023 - 2032 (USD Million)
  • TABLE 285. Mexico pharmacovigilance market, by process, 2018-2022 (USD Million)
  • TABLE 286. Mexico pharmacovigilance market, by process, 2023-2032 (USD Million)
  • TABLE 287. Mexico pharmacovigilance market, by activity, 2018-2022 (USD Million)
  • TABLE 288. Mexico pharmacovigilance market, by activity, 2023-2032 (USD Million)
  • TABLE 289. Mexico pharmacovigilance market, by clinical trial phase, 2018-2022 (USD Million)
  • TABLE 290. Mexico pharmacovigilance market, by clinical trial phase, 2023 - 2032 (USD Million)
  • TABLE 291. Mexico pharmacovigilance market, by service provider, 2018-2022 (USD Million)
  • TABLE 292. Mexico pharmacovigilance market, by service provider, 2023-2032 (USD Million)
  • TABLE 293. Mexico pharmacovigilance market, by end-use, 2018-2022 (USD Million)
  • TABLE 294. Mexico pharmacovigilance market, by end-use, 2023 - 2032 (USD Million)
  • TABLE 295. Argentina pharmacovigilance market, by type, 2018-2022 (USD Million)
  • TABLE 296. Argentina pharmacovigilance market, by type, 2023 - 2032 (USD Million)
  • TABLE 297. Argentina pharmacovigilance market, by process, 2018-2022 (USD Million)
  • TABLE 298. Argentina pharmacovigilance market, by process, 2023-2032 (USD Million)
  • TABLE 299. Argentina pharmacovigilance market, by activity, 2018-2022 (USD Million)
  • TABLE 300. Argentina pharmacovigilance market, by activity, 2023-2032 (USD Million)
  • TABLE 301. Argentina pharmacovigilance market, by clinical trial phase, 2018-2022 (USD Million)
  • TABLE 302. Argentina pharmacovigilance market, by clinical trial phase, 2023 - 2032 (USD Million)
  • TABLE 303. Argentina pharmacovigilance market, by service provider, 2018-2022 (USD Million)
  • TABLE 304. Argentina pharmacovigilance market, by service provider, 2023-2032 (USD Million)
  • TABLE 305. Argentina pharmacovigilance market, by end-use, 2018-2022 (USD Million)
  • TABLE 306. Argentina pharmacovigilance market, by end-use, 2023 - 2032 (USD Million)
  • TABLE 307. Rest of Latin America pharmacovigilance market, by type, 2018-2022 (USD Million)
  • TABLE 308. Rest of Latin America pharmacovigilance market, by type, 2023 - 2032 (USD Million)
  • TABLE 309. Rest of Latin America pharmacovigilance market, by process, 2018-2022 (USD Million)
  • TABLE 310. Rest of Latin America pharmacovigilance market, by process, 2023-2032 (USD Million)
  • TABLE 311. Rest of Latin America pharmacovigilance market, by activity, 2018-2022 (USD Million)
  • TABLE 312. Rest of Latin America pharmacovigilance market, by activity, 2023-2032 (USD Million)
  • TABLE 313. Rest of Latin America pharmacovigilance market, by clinical trial phase, 2018-2022 (USD Million)
  • TABLE 314. Rest of Latin America pharmacovigilance market, by clinical trial phase, 2023 - 2032 (USD Million)
  • TABLE 315. Rest of Latin America pharmacovigilance market, by service provider, 2018-2022 (USD Million)
  • TABLE 316. Rest of Latin America pharmacovigilance market, by service provider, 2023-2032 (USD Million)
  • TABLE 317. Rest of Latin America pharmacovigilance market, by end-use, 2018-2022 (USD Million)
  • TABLE 318. Rest of Latin America pharmacovigilance market, by end-use, 2023 - 2032 (USD Million)
  • TABLE 319. MEA pharmacovigilance market, by country, 2018-2022 (USD Million)
  • TABLE 320. MEA pharmacovigilance market, by country, 2023 - 2032 (USD Million)
  • TABLE 321. MEA pharmacovigilance market, by type, 2018-2022 (USD Million)
  • TABLE 322. MEA pharmacovigilance market, by type, 2023 - 2032 (USD Million)
  • TABLE 323. MEA pharmacovigilance market, by process, 2018-2022 (USD Million)
  • TABLE 324. MEA pharmacovigilance market, by process, 2023-2032 (USD Million)
  • TABLE 325. MEA pharmacovigilance market, by activity, 2018-2022 (USD Million)
  • TABLE 326. MEA pharmacovigilance market, by activity, 2023-2032 (USD Million)
  • TABLE 327. MEA pharmacovigilance market, by clinical trial phase, 2018-2022 (USD Million)
  • TABLE 328. MEA pharmacovigilance market, by clinical trial phase, 2023 - 2032 (USD Million)
  • TABLE 329. MEA pharmacovigilance market, by service provider, 2018-2022 (USD Million)
  • TABLE 330. MEA pharmacovigilance market, by service provider, 2023-2032 (USD Million)
  • TABLE 331. MEA pharmacovigilance market, by end-use, 2018-2022 (USD Million)
  • TABLE 332. MEA pharmacovigilance market, by end-use, 2023 - 2032 (USD Million)
  • TABLE 333. South Africa pharmacovigilance market, by type, 2018-2022 (USD Million)
  • TABLE 334. South Africa pharmacovigilance market, by type, 2023 - 2032 (USD Million)
  • TABLE 335. South Africa pharmacovigilance market, by process, 2018-2022 (USD Million)
  • TABLE 336. South Africa pharmacovigilance market, by process, 2023-2032 (USD Million)
  • TABLE 337. South Africa pharmacovigilance market, by activity, 2018-2022 (USD Million)
  • TABLE 338. South Africa pharmacovigilance market, by activity, 2023-2032 (USD Million)
  • TABLE 339. South Africa pharmacovigilance market, by clinical trial phase, 2018-2022 (USD Million)
  • TABLE 340. South Africa pharmacovigilance market, by clinical trial phase, 2023 - 2032 (USD Million)
  • TABLE 341. South Africa pharmacovigilance market, by service provider, 2018-2022 (USD Million)
  • TABLE 342. South Africa pharmacovigilance market, by service provider, 2023-2032 (USD Million)
  • TABLE 343. South Africa pharmacovigilance market, by end-use, 2018-2022 (USD Million)
  • TABLE 344. South Africa pharmacovigilance market, by end-use, 2023 - 2032 (USD Million)
  • TABLE 345. Saudi Arabia pharmacovigilance market, by type, 2018-2022 (USD Million)
  • TABLE 346. Saudi Arabia pharmacovigilance market, by type, 2023 - 2032 (USD Million)
  • TABLE 347. Saudi Arabia pharmacovigilance market, by process, 2018-2022 (USD Million)
  • TABLE 348. Saudi Arabia pharmacovigilance market, by process, 2023-2032 (USD Million)
  • TABLE 349. Saudi Arabia pharmacovigilance market, by activity, 2018-2022 (USD Million)
  • TABLE 350. Saudi Arabia pharmacovigilance market, by activity, 2023-2032 (USD Million)
  • TABLE 351. Saudi Arabia pharmacovigilance market, by clinical trial phase, 2018-2022 (USD Million)
  • TABLE 352. Saudi Arabia pharmacovigilance market, by clinical trial phase, 2023 - 2032 (USD Million)
  • TABLE 353. Saudi Arabia pharmacovigilance market, by service provider, 2018-2022 (USD Million)
  • TABLE 354. Saudi Arabia pharmacovigilance market, by service provider, 2023-2032 (USD Million)
  • TABLE 355. Saudi Arabia pharmacovigilance market, by end-use, 2018-2022 (USD Million)
  • TABLE 356. Saudi Arabia pharmacovigilance market, by end-use, 2023 - 2032 (USD Million)
  • TABLE 357. UAE pharmacovigilance market, by type, 2018-2022 (USD Million)
  • TABLE 358. UAE pharmacovigilance market, by type, 2023 - 2032 (USD Million)
  • TABLE 359. UAE pharmacovigilance market, by process, 2018-2022 (USD Million)
  • TABLE 360. UAE pharmacovigilance market, by process, 2023-2032 (USD Million)
  • TABLE 361. UAE pharmacovigilance market, by activity, 2018-2022 (USD Million)
  • TABLE 362. UAE pharmacovigilance market, by activity, 2023-2032 (USD Million)
  • TABLE 363. UAE pharmacovigilance market, by clinical trial phase, 2018-2022 (USD Million)
  • TABLE 364. UAE pharmacovigilance market, by clinical trial phase, 2023 - 2032 (USD Million)
  • TABLE 365. UAE pharmacovigilance market, by service provider, 2018-2022 (USD Million)
  • TABLE 366. UAE pharmacovigilance market, by service provider, 2023-2032 (USD Million)
  • TABLE 367. UAE pharmacovigilance market, by end-use, 2018-2022 (USD Million)
  • TABLE 368. UAE pharmacovigilance market, by end-use, 2023 - 2032 (USD Million)
  • TABLE 369. Qatar pharmacovigilance market, by type, 2018-2022 (USD Million)
  • TABLE 370. Qatar pharmacovigilance market, by type, 2023 - 2032 (USD Million)
  • TABLE 371. Qatar pharmacovigilance market, by process, 2018-2022 (USD Million)
  • TABLE 372. Qatar pharmacovigilance market, by process, 2023-2032 (USD Million)
  • TABLE 373. Qatar pharmacovigilance market, by activity, 2018-2022 (USD Million)
  • TABLE 374. Qatar pharmacovigilance market, by activity, 2023-2032 (USD Million)
  • TABLE 375. Qatar pharmacovigilance market, by clinical trial phase, 2018-2022 (USD Million)
  • TABLE 376. Qatar pharmacovigilance market, by clinical trial phase, 2023 - 2032 (USD Million)
  • TABLE 377. Qatar pharmacovigilance market, by service provider, 2018-2022 (USD Million)
  • TABLE 378. Qatar pharmacovigilance market, by service provider, 2023-2032 (USD Million)
  • TABLE 379. Qatar pharmacovigilance market, by end-use, 2018-2022 (USD Million)
  • TABLE 380. Qatar pharmacovigilance market, by end-use, 2023 - 2032 (USD Million)
  • TABLE 381. Israel pharmacovigilance market, by type, 2018-2022 (USD Million)
  • TABLE 382. Israel pharmacovigilance market, by type, 2023 - 2032 (USD Million)
  • TABLE 383. Israel pharmacovigilance market, by process, 2018-2022 (USD Million)
  • TABLE 384. Israel pharmacovigilance market, by process, 2023-2032 (USD Million)
  • TABLE 385. Israel pharmacovigilance market, by activity, 2018-2022 (USD Million)
  • TABLE 386. Israel pharmacovigilance market, by activity, 2023-2032 (USD Million)
  • TABLE 387. Israel pharmacovigilance market, by clinical trial phase, 2018-2022 (USD Million)
  • TABLE 388. Israel pharmacovigilance market, by clinical trial phase, 2023 - 2032 (USD Million)
  • TABLE 389. Israel pharmacovigilance market, by service provider, 2018-2022 (USD Million)
  • TABLE 390. Israel pharmacovigilance market, by service provider, 2023-2032 (USD Million)
  • TABLE 391. Israel pharmacovigilance market, by end-use, 2018-2022 (USD Million)
  • TABLE 392. Israel pharmacovigilance market, by end-use, 2023 - 2032 (USD Million)
  • TABLE 393. Rest of Middle East & Africa pharmacovigilance market, by type, 2018-2022 (USD Million)
  • TABLE 394. Rest of Middle East & Africa pharmacovigilance market, by type, 2023 - 2032 (USD Million)
  • TABLE 395. Rest of Middle East & Africa pharmacovigilance market, by process, 2018-2022 (USD Million)
  • TABLE 396. Rest of Middle East & Africa pharmacovigilance market, by process, 2023-2032 (USD Million)
  • TABLE 397. Rest of Middle East & Africa pharmacovigilance market, by activity, 2018-2022 (USD Million)
  • TABLE 398. Rest of Middle East & Africa pharmacovigilance market, by activity, 2023-2032 (USD Million)
  • TABLE 399. Rest of Middle East & Africa pharmacovigilance market, by clinical trial phase, 2018-2022 (USD Million)
  • TABLE 400. Rest of Middle East & Africa pharmacovigilance market, by clinical trial phase, 2023 - 2032 (USD Million)
  • TABLE 401. Rest of Middle East & Africa pharmacovigilance market, by service provider, 2018-2022 (USD Million)
  • TABLE 402. Rest of Middle East & Africa pharmacovigilance market, by service provider, 2023-2032 (USD Million)
  • TABLE 403. Rest of Middle East & Africa pharmacovigilance market, by end-use, 2018-2022 (USD Million)
  • TABLE 404. Rest of Middle East & Africa pharmacovigilance market, by end-use, 2023 - 2032 (USD Million)

Charts & Figures

  • FIG. 1 GMI report coverage: Critical research elements
  • FIG. 2 Industry segmentation
  • FIG. 3 Top-down approach
  • FIG. 4 Market estimation and forecast methodology
  • FIG. 5 Market forecasting methodology
  • FIG. 6 Breakdown of primary participants
  • FIG. 7 Global pharmacovigilance industry 360 degree synopsis, 2018 - 2032 (USD Mn)
  • FIG. 8 Growth potential analysis, by type
  • FIG. 9 Growth potential analysis, by clinical trial phase
  • FIG. 10 Growth potential analysis, by service provider
  • FIG. 11 Growth potential analysis, by end-use
  • FIG. 12 Company matrix analysis
  • FIG. 13 Competitive analysis of major market players
  • FIG. 14 Competitive positioning matrix
  • FIG. 15 Strategic outlook matrix
  • FIG. 16 Company market share analysis, 2022
  • FIG. 17 Strategic dashboard